SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo

Transplantation

Volumn 64, Issue 1, 1997, Pages 36-42

  Schuler, Walter ^a   Sedrani, Richard ^a   Cottens, Sylvain ^a   Häberlin, Barbara ^a   Schulz, Manfred ^a   Schuurman, Henk Jan ^a   Zenke, Gerhard ^a   Zerwes, Hans Günter ^a   Schreier, Max H ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; EVEROLIMUS; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DRUG MECHANISM; GRAFT REJECTION; GROWTH INHIBITION; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PREVENTION; PRIORITY JOURNAL; RAT; STRAIN DIFFERENCE;

ABDOMEN; ADMINISTRATION, ORAL; ANIMALS; CARRIER PROTEINS; CELL DIVISION; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULONEPHRITIS; GRAFT REJECTION; GRAFT VS HOST REACTION; GROWTH INHIBITORS; GROWTH SUBSTANCES; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MERCURIC CHLORIDE; POLYENES; PROTEIN BINDING; RATS; RATS, INBRED BN; RATS, INBRED F344; RATS, WISTAR; SIROLIMUS; TACROLIMUS BINDING PROTEINS; TRANSPLANTATION, HETEROTOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030832514     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199707150-00008     Document Type: Article

References (33)

1. Calne RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989: 2: 227.
2. Morris RE, Meiser BM. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989; 17: 609.
3. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992; 6:39.
4. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660.
5. Hatfield SM, Mynderse JS, Roehm NW. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists. J Pharmacol Exp Ther 1992; 261: 970.
6. Hultsch T, Martin R, Hohman RJ. The effects of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines. Mol Biol Cell 1992; 3: 981.
7. Akselband Y, Harding MW, Nelson PA. Rapamycin inhibits spontaneous and fibroblast growth factor β-stimulated proliferation of endothelial cells and fibroblasts. Transplant Proc 1991; 23: 2833.
8. Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Transplantation 1995; 59: 390.
9. Morris RE, Meiser BM, Wu J, Shorthouse R, Wang J. Use of rapamycin for suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK506, and effect on host-versus-graft and graft-versus-host reactions. Transplant Proc 1991; 23: 521.
10. Tu Y, Stepkowsky SM, Chou T-C, Kahan BD. The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice. Transplantation 1995; 59: 177.
11. Martin DF, DeBarge LR, Nussenblatt RB, Chan CC, Roberge FG. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 1995; 154: 922.
12. Häyry P, Isoniemi H, Yilmaz S, et al. Chronic allograft rejection. Immunol Rev 1993; 134: 39.
13. Gregory CR, Huie P, Billingham ME, Morris RE. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Transplantation 1993; 55: 1409.
14. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59: 655.
15. Granger DK, Cromwell JW, Chen SC, et al. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 1995; 59: 183.
16. DiJoseph JF, Fluhler E, Armsrong J, Sharr M, Sehgal SN. Therapeutic blood levels of sirolimus (rapamycin) in the allografted rat. Transplantation 1996; 62: 1109.
17. Kahan BD, Murgia MG, Slaton J, Napoli K. Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Ther Drug Monit 1995; 17: 672.
18. Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 1.
19. Taesch S, Niese D. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients. Transpl Int 1994; 7(suppl 1): 263.
20. Mueller EA, Kovarik JM, van Bree JB, Lison AE, Kutz K. Safety and steady-state pharmacokinetics of a new oral formulation of cyclosporin A in renal transplant patients. Transpl Int 1994; 7 (suppl 1): 267.
21. Lamb JR, Eckels DD, Lake P, Woody JN, Green N. Human T cell clones recognize chemically synthesized peptides of influenza haemagglutinin. Nature 1982; 300: 66.
22. 2 in the rat: its possible role in an experimental autoimmune disease. Eur J Immunol 1982; 12: 620.
23. Dumont FJ, Melino MR, Staruch MJ, Koprak SL, Fischer PA, Sigal NH. The immunosuppressive macrolides FK506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 1418.
24. Druet P, Pelletier L, Rossert J, Druet E, Hirsch F, Sapin C. Autoimmune reactions induced by metals. In: Kammüller ME, Bloksma N, Seinen W, eds. Autoimmunity and toxicology: immune dysregulation induced by drugs and chemicals. Amsterdam: Elsevier Science Publishers, 1989: 347.
25. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997; 64: 32.
26. Cottens S, Sedrani R. O-Alkylated rapamycin derivatives and their use, particularly as immunosuppressants. PCT International patent application 1994; WO 94/09010-A1. [Chem Abstr 1994; 122: 9774a].
27. Van Duyne JD, Standaert RF, Schreiber SL, Clardy J. Atomic structure of the rapamycin human immunophilin FKBP-12 complex. J Am Chem Soc 1991; 113: 7433.
28. Van Duyne JD, Standaert RF, Karplus PA, Schreiber SL, Clardy J. Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. J Mol Biol 1993; 229: 105.
29. Cottens S, Fehr T, Quesniaux V, Schuler W, Sedrani R, Zenke G. The role of immunophilin binding in the immunosuppressive properties of CsA, FK506 and rapamycin derivatives. Act Chim Ther 1994; 21: 83.
30. Gulanikar AC, MacDonald AS, Sungurtekin U, Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992; 53: 323.
31. Basadonna GP, Matas AJ, Gillingham KJ, et al. Relationship between early vs late acute rejection and onset of chronic rejection in kidney transplantation. Transplant Proc 1993; 25: 910.
32. 1/2). Transplantation 1994; 57: 875.
33. Pirsch JD, Ploeg RJ, Gange S, et al. Determinants of graft survival after renal transplantation. Transplantation 1996; 61: 1581.